MS-553,acalabrutinib,venetoclax,Rituximab,obinutuzumab
roche,astrazeneca,abbvie,mingsight pharma
['ms-553', 'lymsm', 'acalabrutinib', 'cll', 'venetoclax']
congress | #ash22 , presented early results from a study of ms-553, a highly selective pkc inhibitor. enrolled pts had #cll or #sll and were heavily pretreated. mtd was not reached. 48% of pts achieved pr/prl with ms-553 monotherapy.
#lymsm #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm